A comprehensive ligand based mapping of the σ2 receptor binding pocket

Medicinal Chemistry

Volumn 10, Issue 1, 2014, Pages 98-121

  Rhoades, Derek J ^a   Kinder, David H ^b   Mahfouz, Tarek M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

Author keywords

3D QSAR; Pharmacophore; Sigma receptor; Sigma receptor structural model

Indexed keywords

LIGAND; SIGMA OPIATE RECEPTOR;

ARTICLE; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; SIGMA RECEPTOR SYSTEM;

BINDING SITES; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, SIGMA;

EID: 84891361748     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406409999131119103621     Document Type: Article

References (51)

1. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517.
2. Prezzavento, O.; Campisi, A.; Parenti, C.; Ronsisvalle, S.; Giuseppina, A., G.; Arena, E.; Pistolozzi, M.; Scoto, G. M.; Bertucci, C.; Vanella, A.; Ronsisvalle, G. Synthesis and resolution of cis-(±)-methyl(1R,2S/1S,2R)- 2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl) cyclopropanecarboxylate [(±)-PPCC]: new s receptor ligands with neuroprotective effect. J. Med. Chem. 2010, 53, 5881.
3. Yang, Z.; Carter, E. L.; Torbey, M. T.; Martin, L. J.; Koehler, R. C. Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons. Exp. Neurol. 2010, 221, 166.
4. Elbrønd-Bek, H.; Wellejus, A.; Kelly, N. M.; Weidner, M. S.; Jørgensen, S. H. 2-(Cyclohexylamino)-1-(4-cyclopentylpiperazin-1-yl)-2- methylpropan-1-one, a novel compound with neuroprotective and neurotrophic effects in vitro. Neurochem. Int. 2011, 59, 821.
5. Bhuiyan, M. S.; Fukunaga, K. Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin. Ther. Targets 2011, 15, 145.
6. Maurice, R.; Martin-Fardon, R.; Romieu, P.; Matsumoto, R. R. Sigma1 receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci. Biobehav. Rev. 2002, 26, 499.
7. Romieu, P.; Martin-Fardon, R.; Bowen, W. D.; Maurice, T. Sigma-1 receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. 2003, 23, 3572.
8. Akunne, H. C.; Zoski, K. T.; Whetzel, J. J.; Cordon, R. M.; Roman, F.; Pugsley, T. A. Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001, 41, 138.
9. Leonard, B. E. Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 2004, 37, S166.
10. Matsuno, K.; Senda, T.; Kobayashi, T.; Mita, S. Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 1995, 690, 200.
11. Meurs, A.; Clinckers, R.; Ebinger, G.; Michotte, Y.; Smolders, I. Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur. J. Neurosci. 2007, 26, 3079.
12. Banister, S. D.; Yoo, D. T.; Chua, S. W.; Cui, J.; Mach, R. H.; Kassiou, M. N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands. Bioorg. Med. Chem. Lett. 2011, 21, 5289.
13. Waarde, A. V.; Rybczynska, A. A.; Ramakrishnan, N.; Ishiwata, K.; Elsinga, P. H.; Dierckx, R. A. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr. Pharm. Des. 2010, 16, 3519.
14. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; de Costa, B. R.; Rice, K. C. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42, 355.
15. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85.
16. Wolfe, J., S.A.; De Souza, E. B., Eds.; In Sigma receptors in the brain-endocrine-immune axis. In: Kamenka, J.M.; Domino, E.F. (Eds.), Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? NPP Books: Ann Arbor, MI, 1992; pp. 927-958.
17. Su, T. P.; Hayashi, T.; Maurice, T.; Buch, S.; Ruoho, A. E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 2010, 31, 557.
18. Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; Del Pozo, E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr. Neuropharmacol. 2008, 6, 344.
19. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossman, H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 8072.
20. Kekuda, R. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 1996, 229, 553.
21. Langa, F.; Codony, X.; Tovar, V.; Lavado, A.; Giménez, E.; Cozar, P.; Cantero, M.; Dordal, A.; Hernández, E.; Pérez, R.; Monroy, X.; Zamanillo, D.; Guitart, X.; Montoliu, L. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur. J. Neurosci. 2003, 18, 2188.
22. Gebreselassie, D.; Bowen, W. D. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur. J. Pharmacol. 2004, 493, 19.
23. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of s-1 and s-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268, 9.
24. Brent, P. J.; Pang, G. T. Sigma-binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur. J. Pharmacol. 1995, 278, 151.
25. Aydar, E.; Onganer, P.; Perrett, R.; Djamgoz, M. B.; Palmer, C. P. The expression and functional characterization of σ (sigma) 1 receptors in breast cancer cell lines. Cancer Lett. 2006, 242, 245.
26. Crawford, K. W.; Coop, A.; Bowen, W. D. σ2 receptors regulate changes in sphingolipid levels in breast tumor cells. Eur. J. Pharmacol. 2002, 443, 207.
27. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62, 313.
28. Bowen, W. D.; Jin, B.; Blann, E.; Vilner, B. J.; Lyn-Cook, B. D. σ receptor ligands modulate expression of the multi-drug resistance gene in human and rodent brain tumor cell lines. Proc. Am. Assoc. Cancer Res. 2007, 38, 479.
29. Kashiwagi, H.; McDunn, J. E.; Simon Jr., P. O.; Goedegebuure, P. S.; Xu, J.; Jones, L.; Chang, K.; Johnston, F.; Trinkaus, K.; Hotchkiss, R. S.; Mach, R. H.; Hawkins, W. G. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol. Cancer 2007, 6, 48.
30. Hashimoto, K.; Ishiwata, K. Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals. Curr. Pharm. Des. 2006, 12, 3857.
31. Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Zeng, D.; Kung, M. -.; Kung, H. F.; Mach, R. H. Radiosynthesis and biological evaluation of a promising σ2-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Appl. Radiat. Isot. 2010, 68, 2268.
32. Cratteri, P.; Romanelli, M. N.; Cruciani, G.; Bonaccini, C.; Melani, F. GRIND-derived pharmacophore model for a series of alphatropanyl derivative ligands of the sigma-2 receptor. J. Comput. Aided Mol. Des. 2004, 18, 361.
33. Abate, C.; Mosier, P. D.; Berardi, F.; Glennon, R. A. A structureaffinity and comparative molecular field analysis of sigma-2 (σ2) receptor ligands. Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 246.
34. Laurini, E.; Zampieri, D.; Mamolo, M. G.; Vio, L.; Zanette, C.; Florio, C.; Posocco, P.; Fermeglia, M.; Pricl, S. A 3Dpharmacophore model for sig2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. Bioorg. Med. Chem. Lett. 2010, 20, 2954.
35. MAESTRO, version 8.5, Schrodinger, LLC, New York, NY, 2008.
36. MACROMODEL, version 9.6, Schrodinger, LLC, New York, NY, 2008.
37. PHASE, version 2.0, Schrodinger, LLC, New York, NY, 2005.
38. Dixon, S. L.; Smondyrev, A. M.; Rao, S. N. Phase: A novel approach to pharmacophore modeling and 3D database searching. Chem. Biol. Drug Design 2006, 67, 370.
39. Young, F. W. ViSta: The Visual Statistics System. 1996.
40. Weber, E.; Sonders, M.; Quarum, M.; McLean, S.; Pou, S.; Keana, J. F. W. 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma 1 and sigma 2 receptors for psychomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 8784.
41. Bertha, C. M.; Vilner, B. J.; Mattson, M. V.; Bowen, W. D.; Becketts, K.; Xu, H.; Rothman, R. B.; Flippen-Anderson, J. L.; Rice, K. C. (E)-8-Benzylidene Derivatives of 2-Methyl-5-(3-hydroxyphenyl)morphans: Highly Selective Ligands for the σ 2 Receptor Subtype. J. Med. Chem. 1995, 38, 4776.
42. Bowen, W. D.; Bertha, C. M.; Vilner, B. J.; Rice, K. C. CB-64D and CB-184: ligands with high σ2 receptor affinity and subtype selectivity. Eu.r J. Pharmacol. 1995, 278, 257.
43. Vangveravong, S.; Xu, J.; Zeng, C.; Mach, R. H. Synthesis of Nsubstituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands. Bioorg. Med. Chem. 2006, 14, 6988.
44. Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Vangveravong, S.; Luedtke, R. R. Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14, 195.
45. Tu, Z.; Dence, C. S.; Ponde, D. E.; Jones, L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Carbon-11 labeled σ2 receptor ligands for imaging breast cancer. Nucl. Med. Biol. 2005, 32, 423.
46. Maeda, D. Y.; Williams, W.; Kim, W. E.; Thatcher, L. N.; Bowen, W. D.; Coop, A. N-Arylalkylpiperidines as high-affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for selective sigma-2 agents. Bioorg. Med. Chem. Lett. 2002, 12, 497.
47. de Costa, B. R.; He, X.; Dominguez, C.; Cutts, J.; Williams, W.; Bowen, W. D. A new approach to the design of σ-2-selective ligands: Synthesis and evaluation of N-[2-(3, 4-Dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) ethylaminerelated polyamines at σ-1 and σ-2 receptor subtypes. J. Med. Chem. 1994, 37, 314.
48. Bowen, W. D.; Vilner, B. J.; Williams, W.; Bertha, C. M.; Kuehne, M. E.; Jacobson, A. E. Ibogaine and its congeners are σ2 receptorselective ligands with moderate affinity. Eur. J. Pharmacol. 1996, 279, R1.
49. Fan, K.; Lever, J. R.; Lever, S. Z. Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding sigma-1 and sigma-2 receptors. Bioorg. Med. Chem. 2011, 19, 1852.
50. Berardi, F.; Abate, C.; Ferorelli, S.; Uricchio, V.; Colabufo, N. A.; Niso, M.; Perrone, R. Exploring the importance of piperazine Natoms for σ2 receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5- methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-propyl]piperazine (PB28). J. Med. Chem. 2009, 52, 7817.
51. Glennon, R. A. Binding characteristics of σ2 receptor ligands. Braz. J. Pharm. Sci. 2005, 41, 1.